FDA to Review Certain Diabetes Drugs Over New Pancreas Concern (BMY) (LLY) (MRK)
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Join SI Premium – FREE
The FDA is reviewing data on a certain class of diabetes drugs which it says might lead to precancerous changes in the pancreas.
The WSJ notes today that drugs may include Eli Lilly's (NYSE: LLY) Tradjenta, Merck's (NYSE: MCK) Januvia, Novo Nordisk's (NYSE: NVO) Victoza, and Bristol-Myers Squibb's (NYSE: BMY) Byetta.
Labels on the drugs warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, hence the review on the drugs and labeling.
The FDA has not drawn any conclusions yet.
Shares are mixed in late trading.
The WSJ notes today that drugs may include Eli Lilly's (NYSE: LLY) Tradjenta, Merck's (NYSE: MCK) Januvia, Novo Nordisk's (NYSE: NVO) Victoza, and Bristol-Myers Squibb's (NYSE: BMY) Byetta.
Labels on the drugs warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, hence the review on the drugs and labeling.
The FDA has not drawn any conclusions yet.
Shares are mixed in late trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GRI Bio to present Phase 2a IPF drug data at ERS Congress in September
- EU grants Vanda's imsidolimab first orphan status for rare skin disease
- Japan approves Insmed's Brinsupri for lung disease treatment
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
